CIK 0001604821 · Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 010894487
- Phone
- 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,246 | $333.07 | $748K | 2,204,896 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,818 | $334.24 | $942K | 2,202,078 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −3,754 | $335.18 | $1.3M | 2,198,324 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −8,459 | $336.27 | $2.8M | 2,189,865 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,207 | $337.17 | $744K | 2,187,658 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,400 | $338.30 | $474K | 2,186,258 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,100 | $339.37 | $713K | 2,184,158 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,000 | $340.31 | $681K | 2,182,158 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,700 | $341.35 | $922K | 2,179,458 |
| 2026-09-14 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −4,064 | $342.51 | $1.4M | 2,175,394 |
| 2026-09-11 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −800 | $325.01 | $260K | 2,274,594 |
| 2026-09-11 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −3,647 | $326.11 | $1.2M | 2,270,947 |
| 2026-09-11 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −10,556 | $327.14 | $3.5M | 2,260,391 |
| 2026-09-11 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −17,933 | $327.97 | $5.9M | 2,242,458 |
| 2026-09-11 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −15,764 | $328.95 | $5.2M | 2,226,694 |
| 2026-09-11 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,300 | $329.62 | $429K | 2,225,394 |
| 2026-09-02 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −15,160 | $326.89 | $5.0M | 110,859 |
| 2026-09-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −1,000 | $319.76 | $320K | 128,019 |
| 2026-09-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −1,400 | $320.92 | $449K | 126,619 |
| 2026-09-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −600 | $321.91 | $193K | 126,019 |
Page 9 of 39 · 767 trades